每(mei)經(jing)AI快訊，9月12日，天壇生物公(gong)(gong)告，近日，公(gong)(gong)司(si)所屬(shu)成都(dou)蓉(rong)生藥(yao)業有限責任(ren)公(gong)(gong)司(si)（簡稱“成都(dou)蓉(rong)生”）獲得(de)國家藥(yao)監局簽發(fa)的《藥(yao)物臨床(chuang)試(shi)驗批準通知書》，同意(yi)成都(dou)蓉(rong)生按照(zhao)提交(jiao)的方案開展已上市產(chan)品“靜注人免疫(yi)球蛋白（pH4）”（10%,50ml）新(xin)增適應(ying)(ying)癥(zheng)的臨床(chuang)試(shi)驗。新(xin)增適應(ying)(ying)癥(zheng)為慢性(xing)(xing)(xing)炎(yan)性(xing)(xing)(xing)脫髓鞘(qiao)性(xing)(xing)(xing)多(duo)發(fa)性(xing)(xing)(xing)神(shen)(shen)經(jing)根神(shen)(shen)經(jing)病(bing)。